JB Pharma records revenue growth of 12% to INR 1004 crores in Q1 FY25

JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 30th June, 2024.

Financial Performance - Q1 FY25

JB Pharma recorded revenue of INR 1004 crores in first quarter of FY25 registering growth of 12% from INR 896 crores in Q1 FY24. Operating EBITDA* (Earnings before Interest Depreciation and Taxes) improved by 20% to INR 292 crores in Q1 FY25 as compared to INR 243 crores in Q1 FY24. Profit after Taxes registered strong growth of 25% to INR 177 crores in Q1 FY25 vs INR 142 crores in Q1 FY24.

*Operating EBITDA is after excluding non-cash ESOP Charge

Commenting on the financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, "Our overall performance in the first quarter has been robust. We have reached a new milestone of INR 1,000 crores in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin.

Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth. We expect the international business including CDMO business to pick-up in the second half of the financial year.

The good start in the first quarter augurs well for the balance fiscal year. We are confident about meeting our operating and strategic goals for the year and remain focused on making the organisation progressive and future ready.

Source : Equity Bulls

Keywords

JBChemicalsandPharmaceuticals Q1FY25 Q1FY2025 FY2025 ResultUpdate